NEW YORK (GenomeWeb News) – Advanced Cell Diagnostics said Tuesday that it has raised $5.4 million in a Series A financing from Morningside Ventures.

The company plans to use the funding to develop diagnostic tests based on its RNAscope technology.

The RNAscope is a multiplex fluorescent and chromogenic in situ hybridization platform used to detect and quantify RNA biomarkers. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.